|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date01 Jan 1997 |
Effect and Safety of Recombinant Human Interferon α-2b Spray on Herpangina in Pediatric Patients
This is a multicenter, open,randomized controlled trial aiming to evaluate the effectiveness of recombinant human interferon α-2b spray compared with ribavirin treatment on pediatric patients with herpangina.
100 Clinical Results associated with Tianjin Sinobioway Biomedicine Co., Ltd.
0 Patents (Medical) associated with Tianjin Sinobioway Biomedicine Co., Ltd.
100 Deals associated with Tianjin Sinobioway Biomedicine Co., Ltd.
100 Translational Medicine associated with Tianjin Sinobioway Biomedicine Co., Ltd.